

Global Endothelin Antagonists Therapeutics Market Growth 2026-2032

<https://marketpublishers.com/r/G60AD2BB0631EN.html>

Date: April 2026

Pages: 118

Price: US\$ 3,660.00 (Single User License)

ID: G60AD2BB0631EN

Abstracts

The global Endothelin Antagonists Therapeutics market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secretes high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the 'Endothelin Antagonists Therapeutics Industry Forecast' looks at past sales and reviews total world Endothelin Antagonists Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected Endothelin Antagonists Therapeutics sales for 2026 through 2032. With Endothelin Antagonists Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Endothelin Antagonists Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Endothelin Antagonists Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Endothelin Antagonists Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Endothelin Antagonists Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endothelin Antagonists Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endothelin Antagonists Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Endothelin Antagonists Therapeutics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Oral

Parenteral

Segmentation by Application:

Cardiovascular Diseases

Scleroderma

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Gilead Sciences, Inc

Sun Pharmaceutical Industries Ltd

Lupin

Zydus Group

Endo International plc

Mylan NV

Teva Pharmaceutical Industries Ltd

Sigmapharm Laboratories , LLC

Alembic Pharmaceuticals Limited

Hikma Pharmaceuticals PLC

Amneal Pharmaceuticals LLC

AstraZeneca

Johnsons & Johnsons Private limited

GSK Plc

Key Questions Addressed in this Report

What is the 10-year outlook for the global Endothelin Antagonists Therapeutics market?

What factors are driving Endothelin Antagonists Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Endothelin Antagonists Therapeutics market opportunities vary by end market size?

How does Endothelin Antagonists Therapeutics break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Endothelin Antagonists Therapeutics Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Endothelin Antagonists Therapeutics by Country/Region, 2021, 2025 & 2032

2.2 Endothelin Antagonists Therapeutics Segment by Type

- 2.2.1 Oral
- 2.2.2 Parenteral
- 2.2.3 Endothelin Antagonists Therapeutics Sales by Type
 - 2.2.3.1 Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026)

2.3 Endothelin Antagonists Therapeutics Segment by Application

- 2.3.1 Cardiovascular Diseases
- 2.3.2 Scleroderma
- 2.3.3 Other
- 2.3.4 Endothelin Antagonists Therapeutics Sales by Application
 - 2.3.4.1 Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)
 - 2.3.4.2 Global Endothelin Antagonists Therapeutics Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Endothelin Antagonists Therapeutics Sale Price by Application
(2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Endothelin Antagonists Therapeutics Breakdown Data by Company

3.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Company
(2021-2026)

3.1.2 Global Endothelin Antagonists Therapeutics Sales Market Share by Company
(2021-2026)

3.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Company
(2021-2026)

3.2.1 Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026)

3.2.2 Global Endothelin Antagonists Therapeutics Revenue Market Share by Company
(2021-2026)

3.3 Global Endothelin Antagonists Therapeutics Sale Price by Company

3.4 Key Manufacturers Endothelin Antagonists Therapeutics Producing Area
Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Endothelin Antagonists Therapeutics Product Location
Distribution

3.4.2 Players Endothelin Antagonists Therapeutics Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION

4.1 World Historic Endothelin Antagonists Therapeutics Market Size by Geographic
Region (2021-2026)

4.1.1 Global Endothelin Antagonists Therapeutics Annual Sales by Geographic Region
(2021-2026)

4.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Geographic
Region (2021-2026)

4.2 World Historic Endothelin Antagonists Therapeutics Market Size by Country/Region
(2021-2026)

4.2.1 Global Endothelin Antagonists Therapeutics Annual Sales by Country/Region

(2021-2026)

4.2.2 Global Endothelin Antagonists Therapeutics Annual Revenue by Country/Region

(2021-2026)

4.3 Americas Endothelin Antagonists Therapeutics Sales Growth

4.4 APAC Endothelin Antagonists Therapeutics Sales Growth

4.5 Europe Endothelin Antagonists Therapeutics Sales Growth

4.6 Middle East & Africa Endothelin Antagonists Therapeutics Sales Growth

5 AMERICAS

5.1 Americas Endothelin Antagonists Therapeutics Sales by Country

5.1.1 Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026)

5.1.2 Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)

5.2 Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026)

5.3 Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Endothelin Antagonists Therapeutics Sales by Region

6.1.1 APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026)

6.1.2 APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026)

6.2 APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026)

6.3 APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Endothelin Antagonists Therapeutics by Country

7.1.1 Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026)

- 7.1.2 Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
- 7.2 Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
- 7.3 Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Endothelin Antagonists Therapeutics by Country
 - 8.1.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Endothelin Antagonists Therapeutics Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026)
- 8.3 Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics
- 10.3 Manufacturing Process Analysis of Endothelin Antagonists Therapeutics
- 10.4 Industry Chain Structure of Endothelin Antagonists Therapeutics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Endothelin Antagonists Therapeutics Distributors

11.3 Endothelin Antagonists Therapeutics Customer

12 WORLD FORECAST REVIEW FOR ENDOTHELIN ANTAGONISTS THERAPEUTICS BY GEOGRAPHIC REGION

12.1 Global Endothelin Antagonists Therapeutics Market Size Forecast by Region

12.1.1 Global Endothelin Antagonists Therapeutics Forecast by Region (2027-2032)

12.1.2 Global Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Endothelin Antagonists Therapeutics Forecast by Type (2027-2032)

12.7 Global Endothelin Antagonists Therapeutics Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Gilead Sciences, Inc

13.1.1 Gilead Sciences, Inc Company Information

13.1.2 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications

13.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Gilead Sciences, Inc Main Business Overview

13.1.5 Gilead Sciences, Inc Latest Developments

13.2 Sun Pharmaceutical Industries Ltd

13.2.1 Sun Pharmaceutical Industries Ltd Company Information

13.2.2 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications

13.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Sun Pharmaceutical Industries Ltd Main Business Overview

- 13.2.5 Sun Pharmaceutical Industries Ltd Latest Developments
- 13.3 Lupin
 - 13.3.1 Lupin Company Information
 - 13.3.2 Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.3.3 Lupin Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Lupin Main Business Overview
 - 13.3.5 Lupin Latest Developments
- 13.4 Zydus Group
 - 13.4.1 Zydus Group Company Information
 - 13.4.2 Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.4.3 Zydus Group Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Zydus Group Main Business Overview
 - 13.4.5 Zydus Group Latest Developments
- 13.5 Endo International plc
 - 13.5.1 Endo International plc Company Information
 - 13.5.2 Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.5.3 Endo International plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Endo International plc Main Business Overview
 - 13.5.5 Endo International plc Latest Developments
- 13.6 Mylan NV
 - 13.6.1 Mylan NV Company Information
 - 13.6.2 Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.6.3 Mylan NV Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Mylan NV Main Business Overview
 - 13.6.5 Mylan NV Latest Developments
- 13.7 Teva Pharmaceutical Industries Ltd
 - 13.7.1 Teva Pharmaceutical Industries Ltd Company Information
 - 13.7.2 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.7.4 Teva Pharmaceutical Industries Ltd Main Business Overview
- 13.7.5 Teva Pharmaceutical Industries Ltd Latest Developments
- 13.8 Sigmapharm Laboratories , LLC
 - 13.8.1 Sigmapharm Laboratories , LLC Company Information
 - 13.8.2 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Sigmapharm Laboratories , LLC Main Business Overview
 - 13.8.5 Sigmapharm Laboratories , LLC Latest Developments
- 13.9 Alembic Pharmaceuticals Limited
 - 13.9.1 Alembic Pharmaceuticals Limited Company Information
 - 13.9.2 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Alembic Pharmaceuticals Limited Main Business Overview
 - 13.9.5 Alembic Pharmaceuticals Limited Latest Developments
- 13.10 Hikma Pharmaceuticals PLC
 - 13.10.1 Hikma Pharmaceuticals PLC Company Information
 - 13.10.2 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Hikma Pharmaceuticals PLC Main Business Overview
 - 13.10.5 Hikma Pharmaceuticals PLC Latest Developments
- 13.11 Amneal Pharmaceuticals LLC
 - 13.11.1 Amneal Pharmaceuticals LLC Company Information
 - 13.11.2 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.11.4 Amneal Pharmaceuticals LLC Main Business Overview
 - 13.11.5 Amneal Pharmaceuticals LLC Latest Developments
- 13.12 AstraZeneca
 - 13.12.1 AstraZeneca Company Information
 - 13.12.2 AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
 - 13.12.3 AstraZeneca Endothelin Antagonists Therapeutics Sales, Revenue, Price and

Gross Margin (2021-2026)

13.12.4 AstraZeneca Main Business Overview

13.12.5 AstraZeneca Latest Developments

13.13 Johnsons & Johnsons Private limited

13.13.1 Johnsons & Johnsons Private limited Company Information

13.13.2 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics

Product Portfolios and Specifications

13.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics

Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Johnsons & Johnsons Private limited Main Business Overview

13.13.5 Johnsons & Johnsons Private limited Latest Developments

13.14 GSK Plc

13.14.1 GSK Plc Company Information

13.14.2 GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications

13.14.3 GSK Plc Endothelin Antagonists Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 GSK Plc Main Business Overview

13.14.5 GSK Plc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Endothelin Antagonists Therapeutics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Endothelin Antagonists Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Oral

Table 4. Major Players of Parenteral

Table 5. Global Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)

Table 6. Global Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)

Table 7. Global Endothelin Antagonists Therapeutics Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)

Table 9. Global Endothelin Antagonists Therapeutics Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Endothelin Antagonists Therapeutics Sale by Application (2021-2026) & (K Units)

Table 11. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2021-2026)

Table 12. Global Endothelin Antagonists Therapeutics Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application (2021-2026)

Table 14. Global Endothelin Antagonists Therapeutics Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Endothelin Antagonists Therapeutics Sales by Company (2021-2026) & (K Units)

Table 16. Global Endothelin Antagonists Therapeutics Sales Market Share by Company (2021-2026)

Table 17. Global Endothelin Antagonists Therapeutics Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company (2021-2026)

Table 19. Global Endothelin Antagonists Therapeutics Sale Price by Company

(2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Endothelin Antagonists Therapeutics Producing Area Distribution and Sales Area

Table 21. Players Endothelin Antagonists Therapeutics Products Offered

Table 22. Endothelin Antagonists Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Endothelin Antagonists Therapeutics Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Endothelin Antagonists Therapeutics Sales Market Share Geographic Region (2021-2026)

Table 27. Global Endothelin Antagonists Therapeutics Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Endothelin Antagonists Therapeutics Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021-2026)

Table 31. Global Endothelin Antagonists Therapeutics Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Endothelin Antagonists Therapeutics Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)

Table 34. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)

Table 35. Americas Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)

Table 37. Americas Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)

Table 38. APAC Endothelin Antagonists Therapeutics Sales by Region (2021-2026) & (K Units)

Table 39. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region (2021-2026)

Table 40. APAC Endothelin Antagonists Therapeutics Revenue by Region (2021-2026)

& (\$ millions)

Table 41. APAC Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)

Table 42. APAC Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)

Table 43. Europe Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)

Table 44. Europe Endothelin Antagonists Therapeutics Revenue by Country (2021-2026) & (\$ millions)

Table 45. Europe Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)

Table 46. Europe Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)

Table 47. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)

Table 49. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Endothelin Antagonists Therapeutics Sales by Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Endothelin Antagonists Therapeutics

Table 52. Key Market Challenges & Risks of Endothelin Antagonists Therapeutics

Table 53. Key Industry Trends of Endothelin Antagonists Therapeutics

Table 54. Endothelin Antagonists Therapeutics Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Endothelin Antagonists Therapeutics Distributors List

Table 57. Endothelin Antagonists Therapeutics Customer List

Table 58. Global Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)

Table 59. Global Endothelin Antagonists Therapeutics Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 60. Americas Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)

Table 61. Americas Endothelin Antagonists Therapeutics Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Endothelin Antagonists Therapeutics Sales Forecast by Region (2027-2032) & (K Units)

Table 63. APAC Endothelin Antagonists Therapeutics Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Endothelin Antagonists Therapeutics Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Endothelin Antagonists Therapeutics Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Endothelin Antagonists Therapeutics Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Endothelin Antagonists Therapeutics Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Endothelin Antagonists Therapeutics Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Gilead Sciences, Inc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 73. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 74. Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Gilead Sciences, Inc Main Business

Table 76. Gilead Sciences, Inc Latest Developments

Table 77. Sun Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 78. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 79. Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Sun Pharmaceutical Industries Ltd Main Business

Table 81. Sun Pharmaceutical Industries Ltd Latest Developments

Table 82. Lupin Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 83. Lupin Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 84. Lupin Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. Lupin Main Business

Table 86. Lupin Latest Developments

Table 87. Zydus Group Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 88. Zydus Group Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 89. Zydus Group Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Zydus Group Main Business

Table 91. Zydus Group Latest Developments

Table 92. Endo International plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 93. Endo International plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 94. Endo International plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Endo International plc Main Business

Table 96. Endo International plc Latest Developments

Table 97. Mylan NV Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 98. Mylan NV Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 99. Mylan NV Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Mylan NV Main Business

Table 101. Mylan NV Latest Developments

Table 102. Teva Pharmaceutical Industries Ltd Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 103. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 104. Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Teva Pharmaceutical Industries Ltd Main Business

Table 106. Teva Pharmaceutical Industries Ltd Latest Developments

Table 107. Sigmapharm Laboratories , LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 108. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications

- Table 109. Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 110. Sigmapharm Laboratories , LLC Main Business
- Table 111. Sigmapharm Laboratories , LLC Latest Developments
- Table 112. Alembic Pharmaceuticals Limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
- Table 113. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product Portfolios and Specifications
- Table 114. Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 115. Alembic Pharmaceuticals Limited Main Business
- Table 116. Alembic Pharmaceuticals Limited Latest Developments
- Table 117. Hikma Pharmaceuticals PLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
- Table 118. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
- Table 119. Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 120. Hikma Pharmaceuticals PLC Main Business
- Table 121. Hikma Pharmaceuticals PLC Latest Developments
- Table 122. Amneal Pharmaceuticals LLC Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
- Table 123. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product Portfolios and Specifications
- Table 124. Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 125. Amneal Pharmaceuticals LLC Main Business
- Table 126. Amneal Pharmaceuticals LLC Latest Developments
- Table 127. AstraZeneca Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
- Table 128. AstraZeneca Endothelin Antagonists Therapeutics Product Portfolios and Specifications
- Table 129. AstraZeneca Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 130. AstraZeneca Main Business
- Table 131. AstraZeneca Latest Developments
- Table 132. Johnsons & Johnsons Private limited Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors
- Table 133. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics

Product Portfolios and Specifications

Table 134. Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 135. Johnsons & Johnsons Private limited Main Business

Table 136. Johnsons & Johnsons Private limited Latest Developments

Table 137. GSK Plc Basic Information, Endothelin Antagonists Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 138. GSK Plc Endothelin Antagonists Therapeutics Product Portfolios and Specifications

Table 139. GSK Plc Endothelin Antagonists Therapeutics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 140. GSK Plc Main Business

Table 141. GSK Plc Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Endothelin Antagonists Therapeutics
- Figure 2. Endothelin Antagonists Therapeutics Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Endothelin Antagonists Therapeutics Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Endothelin Antagonists Therapeutics Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Endothelin Antagonists Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2025)
- Figure 10. Endothelin Antagonists Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Oral
- Figure 12. Product Picture of Parenteral
- Figure 13. Global Endothelin Antagonists Therapeutics Sales Market Share by Type in 2026
- Figure 14. Global Endothelin Antagonists Therapeutics Revenue Market Share by Type (2021-2026)
- Figure 15. Endothelin Antagonists Therapeutics Consumed in Cardiovascular Diseases
- Figure 16. Global Endothelin Antagonists Therapeutics Market: Cardiovascular Diseases (2021-2026) & (K Units)
- Figure 17. Endothelin Antagonists Therapeutics Consumed in Scleroderma
- Figure 18. Global Endothelin Antagonists Therapeutics Market: Scleroderma (2021-2026) & (K Units)
- Figure 19. Endothelin Antagonists Therapeutics Consumed in Other
- Figure 20. Global Endothelin Antagonists Therapeutics Market: Other (2021-2026) & (K Units)
- Figure 21. Global Endothelin Antagonists Therapeutics Sale Market Share by Application (2025)
- Figure 22. Global Endothelin Antagonists Therapeutics Revenue Market Share by Application in 2026
- Figure 23. Endothelin Antagonists Therapeutics Sales by Company in 2026 (K Units)

Figure 24. Global Endothelin Antagonists Therapeutics Sales Market Share by Company in 2026

Figure 25. Endothelin Antagonists Therapeutics Revenue by Company in 2026 (\$ millions)

Figure 26. Global Endothelin Antagonists Therapeutics Revenue Market Share by Company in 2026

Figure 27. Global Endothelin Antagonists Therapeutics Sales Market Share by Geographic Region (2021-2026)

Figure 28. Global Endothelin Antagonists Therapeutics Revenue Market Share by Geographic Region in 2026

Figure 29. Americas Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)

Figure 30. Americas Endothelin Antagonists Therapeutics Revenue 2021-2026 (\$ millions)

Figure 31. APAC Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)

Figure 32. APAC Endothelin Antagonists Therapeutics Revenue 2021-2026 (\$ millions)

Figure 33. Europe Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)

Figure 34. Europe Endothelin Antagonists Therapeutics Revenue 2021-2026 (\$ millions)

Figure 35. Middle East & Africa Endothelin Antagonists Therapeutics Sales 2021-2026 (K Units)

Figure 36. Middle East & Africa Endothelin Antagonists Therapeutics Revenue 2021-2026 (\$ millions)

Figure 37. Americas Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026

Figure 38. Americas Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)

Figure 39. Americas Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)

Figure 40. Americas Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)

Figure 41. United States Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 42. Canada Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 43. Mexico Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 44. Brazil Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 45. APAC Endothelin Antagonists Therapeutics Sales Market Share by Region in

2026

Figure 46. APAC Endothelin Antagonists Therapeutics Revenue Market Share by Region (2021-2026)

Figure 47. APAC Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)

Figure 48. APAC Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)

Figure 49. China Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 50. Japan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 51. South Korea Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 52. Southeast Asia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 53. India Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 54. Australia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 55. China Taiwan Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 56. Europe Endothelin Antagonists Therapeutics Sales Market Share by Country in 2026

Figure 57. Europe Endothelin Antagonists Therapeutics Revenue Market Share by Country (2021-2026)

Figure 58. Europe Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)

Figure 59. Europe Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)

Figure 60. Germany Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 61. France Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 62. UK Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 63. Italy Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 64. Russia Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 65. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Country (2021-2026)

Figure 66. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Type (2021-2026)

Figure 67. Middle East & Africa Endothelin Antagonists Therapeutics Sales Market Share by Application (2021-2026)

Figure 68. Egypt Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 69. South Africa Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 70. Israel Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 71. Turkey Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 72. GCC Countries Endothelin Antagonists Therapeutics Revenue Growth 2021-2026 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Endothelin Antagonists Therapeutics in 2026

Figure 74. Manufacturing Process Analysis of Endothelin Antagonists Therapeutics

Figure 75. Industry Chain Structure of Endothelin Antagonists Therapeutics

Figure 76. Channels of Distribution

Figure 77. Global Endothelin Antagonists Therapeutics Sales Market Forecast by Region (2027-2032)

Figure 78. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Region (2027-2032)

Figure 79. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Type (2027-2032)

Figure 80. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Type (2027-2032)

Figure 81. Global Endothelin Antagonists Therapeutics Sales Market Share Forecast by Application (2027-2032)

Figure 82. Global Endothelin Antagonists Therapeutics Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Endothelin Antagonists Therapeutics Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G60AD2BB0631EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G60AD2BB0631EN.html>